1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Immunology
  4. Volume 26, 2005
  5. Article

Annual Review of Immunology

Volume 26, 2005

Doing What I Like

Abstract

I have spent my entire professional life at Harvard Medical School, beginning as a medical student. I have enjoyed each day of a diverse career in four medical subspecialties while following the same triad of preclinical areas of investigation—cysteinyl leukotrienes, mast cells, and complement—with occasional translational opportunities. I did not envision a career with a predominant preclinical component. Such a path simply evolved because I chose instinctively at multiple junctures to follow what proved to be propitious opportunities. My commentary notes some of the highlights for each area of interest and the mentors, collaborators, and trainees whose counsel has been immensely important at particular intervals or over an extended period.

Keyword(s): alternative complement pathway, Autobiography, cysteinyl leukotrienes, mast cell, mast cell progenitors, slow reacting substance of anaphylaxis
Loading

Article metrics loading...

/content/journals/10.1146/annurev.immunol.26.021607.090339
2008-04-23
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/iy/26/1/annurev.immunol.26.021607.090339.html?itemId=/content/journals/10.1146/annurev.immunol.26.021607.090339&mimeType=html&fmt=ahah

Literature Cited

  1. Austen KF.1.  1978. Homeostasis of effector systems which can also be recruited for immunologic reactions. Pres. Address Am. Assoc. Immunol. J. Immunol. 121:793–805 [Google Scholar]
  2. Austen KF, Koch-Weser J, Field RA. 2.  1956. Cardiorespiratory problems in severe poliomyelitis observed during the recent epidemic. N. Engl. J. Med. 254:790–93 [Google Scholar]
  3. Drazen JM. 3.  2004. Presentation of the Kober Medal to K. Frank Austen.. J. Clin. Invest. 114:1174–76 [Google Scholar]
  4. Livingstone JB, Austen KF, Kunz LJ. 4.  1957. A study of intercurrent bacterial respiratory infections in bulbospinal poliomyelitis. N. Engl. J. Med. 257:861–66 [Google Scholar]
  5. Austen KF, Carmichael MW, Adams RD. 5.  1957. Neurologic manifestations of chronic pulmonary insufficiency. N. Engl. J. Med. 257:579–90 [Google Scholar]
  6. Austen KF, Rubini ME, Meroney WH, Wolff J. 6.  1958. Salicylates and thyroid function. I. Depression of thyroid function. J. Clin. Invest. 37:1131–43 [Google Scholar]
  7. Wolff J, Austen KF. 7.  1958. Salicylates and thyroid function. II. The effect on the thyroid-pituitary interrelation. J. Clin. Invest. 37:1144–52 [Google Scholar]
  8. Austen KF. 8.  1960. The differentiation of the chloroform, peptone and antigen antibody inducible esterase activities of human serum from plasmin. Immunology 3:152–73 [Google Scholar]
  9. Austen KF, Brocklehurst WE. 9.  1961. Anaphylaxis in chopped guinea pig lung. I. Effect of peptidase substrates and inhibitors. J. Exp. Med. 113:521–39 [Google Scholar]
  10. Austen KF, Brocklehurst WE. 10.  1961. Anaphylaxis in chopped guinea pig lung. II. Enhancement of the anaphylactic release of histamine and slow reacting substance by certain dibasic aliphatic acids and inhibition by monobasic fatty acids. J. Exp. Med. 113:541–57 [Google Scholar]
  11. Austen KF, Brocklehurst WE. 11.  1961. Anaphylaxis in chopped guinea pig lung. III. Effect of carbon monoxide, cyanide, salicylaldoxine, and ionic strength. J. Exp. Med. 114:29–42 [Google Scholar]
  12. Humphrey JH, Austen KF, Rapp HJ. 12.  1963. In vitro studies of reversed anaphylaxis with rat cells. Immunology 6:226–45 [Google Scholar]
  13. Stroud RM, Austen KF, Mayer MM. 13.  1965. Catalysis of C'2 fixation by C'1a: reaction kinetics, competitive inhibition by TAMe, and transferase hypothesis of the enzymatic action of C'1a on C'2, one of its natural substrates. Immunochemistry 2:219–34 [Google Scholar]
  14. Murphy RC, Hammarstrom S, Samuelsson B. 14.  1979. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 76:4275–79 [Google Scholar]
  15. Stechschulte DJ, Austen KF, Bloch KJ. 15.  1967. Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J. Exp. Med. 125:127–47 [Google Scholar]
  16. Orange RP, Stechschulte DJ, Austen KF. 16.  1970. Immunochemical and biologic properties of rat IgE. II. Capacity to mediate the immunologic release of histamine and slow reacting substance of anaphylaxis (SRS-A). J. Immunol. 105:1087–95 [Google Scholar]
  17. Ishizaka T, Ishizaka K, Orange RP, Austen KF. 17.  1970. The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J. Immunol. 104:335–43 [Google Scholar]
  18. Morse HC, Bloch KJ, Austen KF. 18.  1968. Biologic properties of rat antibodies. II. Time-course of appearance of antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-arat): association of this activity with rat IgGa. J. Immunol. 101:658–63 [Google Scholar]
  19. Orange RP, Murphy RC, Karnovsky ML, Austen KF. 19.  1973. The physicochemical characteristics and purification of slow reacting substance of anaphylaxis. J. Immunol. 110:760–70 [Google Scholar]
  20. Orange RP, Murphy RC, Austen KF. 20.  1974. Inactivation of slow reacting substance of anaphylaxis (SRS-A) by arylsulfatases. J. Immunol. 113:316–22 [Google Scholar]
  21. Weller PF, Corey EJ, Austen KF, Lewis RA. 21.  1986. Inhibition of homogeneous human eosinophil arylsulfatase B by sulfidopeptide leukotrienes. J. Biol. Chem. 261:1737–44 [Google Scholar]
  22. Jakschik BA, Falkenhein S, Parker CW. 22.  1977. Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 74:4577–81 [Google Scholar]
  23. Lewis RA, Wasserman SI, Goetzl EJ, Austen KF. 23.  1974. Formation of slow-reacting substance of anaphylaxis in human lung tissue and cells before release. J. Exp. Med. 140:1133–46 [Google Scholar]
  24. Lam BK, Owen WF Jr, Austen KF, Soberman RJ. 24.  1989. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J. Biol. Chem. 264:12885–89 [Google Scholar]
  25. Drazen JM, Austen KF. 25.  1974. Effects of intravenous administration of slow reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2 on pulmonary mechanics in the guinea pig. J. Clin. Invest. 53:1679–85 [Google Scholar]
  26. Marfat A, Corey EJ. 26.  1985. Synthesis and structure elucidation of leukotrienes. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research ed. JE Pike, DR Morton Jr 14155–228 New York: Raven [Google Scholar]
  27. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. 27.  1980. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc. Natl. Acad. Sci. USA 77:3710–14 [Google Scholar]
  28. Morris HR, Taylor GW, Piper PJ, Samhoun MN, Tippins JR. 28.  1980. Slow reacting substances (SRSs); the structure identification of SRSs from rat basophil leukemia (RBL-1) cells. Prostaglandins 19:185–201 [Google Scholar]
  29. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. 29.  1980. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem. Biophys. Res. Commun. 96:271–77 [Google Scholar]
  30. Lee TH, Austen KF, Corey EJ, Drazen JM. 30.  1984. Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc. Natl. Acad. Sci. USA 81:4922–25 [Google Scholar]
  31. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G et al.31.  1980. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA 77:4354–58 [Google Scholar]
  32. Lee CW, Lewis RA, Tauber AI, Mehrotra M, Corey EJ, Austen KF. 32.  1983. The myeloperoxidase-dependent metabolism of leukotrienes C4, D4 and E4 to 6-trans-leukotriene B4 diastereoisomers and the subclass-specific S-diastereoisomeric sulfoxides. J. Biol. Chem. 258:15004–10 [Google Scholar]
  33. Yoshimoto T, Soberman RJ, Lewis RA, Austen KF. 33.  1985. Isolation and characterization of leukotriene C4 synthetase of rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 82:8399–403 [Google Scholar]
  34. Yoshimoto T, Soberman RJ, Spur B, Austen KF. 34.  1988. Properties of highly purified leukotriene C4 synthase of guinea pig lung. J. Clin. Invest. 81:866–71 [Google Scholar]
  35. Penrose JF, Gagnon L, Goppelt-Struebe M, Myers P, Lam BK et al.35.  1992. Purification of human leukotriene C4 synthase. Proc. Natl. Acad. Sci. USA 89:11603–6 [Google Scholar]
  36. Lam BK, Penrose JF, Freeman GJ, Austen KF. 36.  1994. Expression cloning of a cDNA for human leukotriene C4 synthase, a novel integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. USA 91:7663–67 [Google Scholar]
  37. Penrose JF, Spector J, Baldasaro M, Xu K, Boyce J et al.37.  1996. Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35. J. Biol. Chem. 271:11356–61 [Google Scholar]
  38. Lam BK, Penrose JF, Rokach J, Xu K, Baldasaro MH, Austen KF. 38.  1996. Molecular cloning, expression, and characterization of mouse leukotriene C4 synthase. Eur. J. Biochem. 238:606–12 [Google Scholar]
  39. Penrose JF, Baldasaro MH, Webster M, Xu K, Austen KF, Lam BK. 39.  1997. Molecular cloning of the gene for mouse leukotriene C4 synthase. Eur. J. Biochem. 248:807–13 [Google Scholar]
  40. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. 40.  2001. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood–derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J. Exp. Med. 193:123–33 [Google Scholar]
  41. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM et al.41.  2003. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc. Natl. Acad. Sci. USA 100:11589–93 [Google Scholar]
  42. Lam BK, Penrose JF, Xu K, Baldasaro MH, Austen KF. 42.  1997. Site-directed mutagenesis of human leukotriene C4 synthase. J. Biol. Chem. 272:13923–28 [Google Scholar]
  43. Schmidt-Krey I, Kanaoka Y, Mills DJ, Irikura D, Haase W et al.43.  2004. Human leukotriene C4 synthase at 4.5 Å resolution in projection. Structure 12:2009–14 [Google Scholar]
  44. Ago H, Kanaoka Y, Irikura D, Lam BK, Shimamura T et al.44.  2007. Crystal structure of LTC4 synthase, the membrane protein for cysteinyl leukotriene biosynthesis. Nature 448:609–12 [Google Scholar]
  45. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. 45.  2001. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276:22608–13 [Google Scholar]
  46. Maekawa A, Kanaoka Y, Lam BK, Austen KF. 46.  2001. Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc. Natl. Acad. Sci. USA 98:2256–61 [Google Scholar]
  47. Maekawa A, Austen KF, Kanaoka Y. 47.  2002. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277:20820–24 [Google Scholar]
  48. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. 48.  2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 44:46129–34 [Google Scholar]
  49. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. 49.  2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 101:3047–52 [Google Scholar]
  50. Caulfield JP, Lewis RA, Hein A, Austen KF. 50.  1980. Secretion in dissociated human pulmonary mast cells: evidence for solubilization of granule contents before discharge. J. Cell Biol. 85:299–312 [Google Scholar]
  51. Schwartz LB, Riedel C, Caulfield JP, Wasserman SI, Austen KF. 51.  1981. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J. Immunol. 126:2071–78 [Google Scholar]
  52. Schwartz LB, Lewis RA, Austen KF. 52.  1981. Tryptase from human pulmonary mast cells. Purification and characterization. J. Biol. Chem. 256:11939–43 [Google Scholar]
  53. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF. 53.  1983. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J. Immunol. 130:1891–95 [Google Scholar]
  54. Reynolds DS, Gurley DS, Stevens RL, Sugarbaker DJ, Austen KF, Serafin WE. 54.  1989. Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases. Proc. Natl. Acad. Sci. USA 86:9480–84 [Google Scholar]
  55. Reynolds DS, Gurley DS, Austen KF. 55.  1992. Cloning and characterization of the novel gene for mast cell carboxypeptidase A. J. Clin. Invest. 89:273–82 [Google Scholar]
  56. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald H-R. 56.  2007. . Molecular mechanism of mast cell-mediated defense against endothelial and snake venom sarafotoxin. J. Exp. Med. 204:2629–39 [Google Scholar]
  57. Reynolds DS, Serafin WE, Faller DV, Wall DA, Abbas AK et al.57.  1988. Immortalization of murine connective tissue-type mast cells at multiple stages of their differentiation by coculture of splenocytes with fibroblasts that produce Kirsten sarcoma virus. J. Biol. Chem. 263:12783–91 [Google Scholar]
  58. Reynolds DS, Stevens RL, Gurley DS, Lane WS, Austen KF, Serafin WE. 58.  1989. Isolation and molecular cloning of mast cell carboxypeptidase A. J. Biol. Chem. 264:20094–99 [Google Scholar]
  59. Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, Serafin WE. 59.  1990. Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. Proc. Natl. Acad. Sci. USA 87:3230–34 [Google Scholar]
  60. Serafin WE, Reynolds DS, Rogelj S, Lane WS, Conder GA et al.60.  1990. Identification and molecular cloning of a novel mouse mucosal mast cell serine protease. J. Biol. Chem. 265:423–29 [Google Scholar]
  61. Serafin WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham P et al.61.  1991. Cloning of the cDNA and gene for mouse mast cell protease 4: demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat. J. Biol. Chem. 266:1934–41 [Google Scholar]
  62. McNeil HP, Austen KF, Somerville LL, Gurish MF, Stevens RL. 62.  1991. Molecular cloning of the mouse mast cell protease-5 gene: a novel secretory granule protease expressed early in the differentiation of serosal mast cells. J. Biol. Chem. 266:20316–22 [Google Scholar]
  63. Reynolds DS, Gurley DS, Austen KF, Serafin WE. 63.  1991. Cloning of the cDNA and gene of mouse mast cell protease-6: transcription by progenitor mast cells and mast cells of the connective tissue subclass. J. Biol. Chem. 266:3847–53 [Google Scholar]
  64. Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N. 64.  1996. Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J. Biol. Chem. 271:2851–55 [Google Scholar]
  65. Hunt JE, Friend DS, Gurish MF, Feyfant E, Sali A et al.65.  1997. Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells. J. Biol. Chem. 272:29158–66 [Google Scholar]
  66. Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. 66.  1992. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J. Exp. Med. 175:1003–12 [Google Scholar]
  67. Ghildyal N, Friend DS, Nicodemus CF, Austen KF, Stevens RL. 67.  1993. Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to interleukin-10. J. Immunol. 151:3206–14 [Google Scholar]
  68. Xia Z, Ghildyal N, Austen KF, Stevens RL. 68.  1996. Post-transcriptional regulation of chymase expression in mast cells: a cytokine-dependent mechanism for controlling the expression of granule neutral proteases of hematopoietic cells. J. Biol. Chem. 271:8747–53 [Google Scholar]
  69. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL. 69.  1996. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J. Cell Biol. 135:279–90 [Google Scholar]
  70. Gurish MF, Pear WS, Stevens RL, Scott ML, Sokol K et al.70.  1995. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity 3:175–86 [Google Scholar]
  71. Yurt RW, Leid RW Jr, Austen KF, Silbert JE. 71.  1977. Native heparin from rat peritoneal mast cells. J. Biol. Chem. 252:518 [Google Scholar]
  72. Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF. 72.  1979. Isolation and characterization of heparin from human lung. J. Clin. Invest. 64:1537–43 [Google Scholar]
  73. Metcalfe DD, Smith JA, Austen KF, Silbert JA. 73.  1980. Polydispersity of rat mast cell heparin. Implications for proteoglycan assembly. J. Biol. Chem. 255:11753–58 [Google Scholar]
  74. Razin E, Stevens RL, Akiyama F, Schmid K, Austen KF. 74.  1982. Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J. Biol. Chem. 257:7229–36 [Google Scholar]
  75. Serafin WE, Katz HR, Austen KF, Stevens RL. 75.  1986. Complexes of heparin proteoglycans, chondroitin sulfate E proteoglycans, and [3H]diisopropyl fluorophosphate-binding proteins are exocytosed from activated mouse bone marrow-derived mast cells. J. Biol. Chem. 261:15017–21 [Google Scholar]
  76. Avraham S, Stevens RL, Gartner MC, Austen KF, Lalley PA, Weis JH. 76.  1988. Isolation of a cDNA that encodes the peptide core of the secretory granule proteoglycan of rat basophilic leukemia-1 cells and assessment of its homology to the human analogue. J. Biol. Chem. 263:7292–96 [Google Scholar]
  77. Stevens RL, Avraham S, Gartner MC, Bruns GAP, Austen KF, Weis JH. 77.  1988. Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 263:7287–91 [Google Scholar]
  78. Avraham S, Austen KF, Nicodemus CF, Gartner MC, Stevens RL. 78.  1989. Cloning and characterization of the mouse gene that encodes the peptide core of secretory granule proteoglycans and expression of this gene in transfected rat-1 fibroblasts. J. Biol. Chem. 264:16719–26 [Google Scholar]
  79. Kitamura Y, Go S, Hatanaka K. 79.  1978. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447–52 [Google Scholar]
  80. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. 80.  1996. Identification of a committed precursor for the mast cell lineage. Science 271:818–22 [Google Scholar]
  81. Crapper RM, Schrader JW. 81.  1983. Frequency of mast cell precursors in normal tissues determined by an in vitro assay: antigen induces parallel increases in the frequency of P cell precursors and mast cells. J. Immunol. 131:923–28 [Google Scholar]
  82. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS et al.82.  2001. Intestinal mast cell progenitors require CD49dβ7 (α4β7 integrin) for tissue-specific homing. J. Exp. Med. 194:1243–52 [Google Scholar]
  83. Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA et al.83.  2005. Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 105:4308–13 [Google Scholar]
  84. Abonia JP, Hallgren J, Jones T, Shi R, Xu Y et al.84.  2006. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 108:1588–94 [Google Scholar]
  85. Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H et al.85.  2005. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. USA 102:18105–10 [Google Scholar]
  86. Katz HR, Benson AC, Austen KF. 86.  1989. Activation and phorbol ester-stimulated phosphorylation of a plasma membrane glycoprotein antigen expressed on mouse IL-3-dependent mast cells and serosal mast cells. J. Immunol. 142:919–26 [Google Scholar]
  87. Arm JP, Gurish MF, Reynolds DS, Scott HC, Gartner CS et al.87.  1991. Molecular cloning of gp49, a cell surface antigen that is preferentially expressed by mouse mast cell progenitors and is a new member of the immunoglobulin superfamily. J. Biol. Chem. 266:15966–73 [Google Scholar]
  88. Castells MC, Wu X, Arm JP, Austen KF, Katz HR. 88.  1994. Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49. J. Biol. Chem. 269:8393–401 [Google Scholar]
  89. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. 89.  1996. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high affinity Fc receptor for IgE. Proc. Natl. Acad. Sci. USA 93:10809–14 [Google Scholar]
  90. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. 90.  2001. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J. Exp. Med. 194:227–33 [Google Scholar]
  91. Feldweg AM, Friend DS, Zhou JS, Kanaoka Y, Daheshia M et al.91.  2003. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur. J. Immunol. 33:2262–68 [Google Scholar]
  92. Zhou JS, Friend DS, Feldweg AM, Daheshia M, Li L et al.92.  2003. Prevention of lipopolysaccharide-induced microangiopathy by gp49B1: evidence for an important role for gp49B1 expression on neutrophils. J. Exp. Med. 198:1243–51 [Google Scholar]
  93. Arm JP, Nwankwo C, Austen KF. 93.  1997. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J. Immunol. 159:2342–49 [Google Scholar]
  94. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. 94.  1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279–85 [Google Scholar]
  95. Fearon DT, Austen KF, Ruddy S. 95.  1973. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 138:1305–13 [Google Scholar]
  96. Fearon DT, Austen KF. 96.  1975. Properdin: binding to C3b and stabilization of the C3b-dependent convertase. J. Exp. Med. 142:856–63 [Google Scholar]
  97. Weiler JM, Daha MR, Austen KF, Fearon DT. 97.  1976. Control of the amplification convertase of complement by the plasma protein β1H. Proc. Natl. Acad. Sci. USA 73:3268–72 [Google Scholar]
  98. Whaley K, Ruddy S. 98.  1976. Modulation of the alternative complement pathways by beta 1H globulin. J. Exp. Med. 144:1147–63 [Google Scholar]
  99. Fearon DT, Austen KF. 99.  1975. Initiation of C3 cleavage in the alternative complement pathway. J. Immunol. 115:1357–61 [Google Scholar]
  100. Fearon DT, Austen KF, Ruddy S. 100.  1974. Properdin factor D: characterization of its active site and isolation of the precursor form. J. Exp. Med. 139:355–66 [Google Scholar]
  101. Fearon DT, Austen KF. 101.  1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA 74:1683–87 [Google Scholar]
  102. Fearon DT, Austen KF. 102.  1977. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J. Exp. Med. l46:22–33 [Google Scholar]
  103. Fearon DT. 103.  1978. Regulation by membrane sialic acid of beta 1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75:1971–75 [Google Scholar]
  104. Soter NA, Lewis RA, Corey EJ, Austen KF. 104.  1983. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin. J. Invest. Dermatol. 80:115–19 [Google Scholar]
  105. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF et al.105.  1982. Bronchoconstrictor effects of leukotriene C in humans. Science 216:196–98 [Google Scholar]
  106. Griffin M, Weiss JW, Leitch AG, McFadden ER Jr, Corey EJ et al.106.  1983. Effects of leukotriene D on the airways in asthma. N. Engl. J. Med. 308:436–39 [Google Scholar]
  107. Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER Jr et al.107.  1987. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic individuals. Am. Rev. Respir. Dis. 135:333–37 [Google Scholar]
  108. Sheffer AL, Austen KF. 108.  1980. Exercise-induced anaphylaxis. J. Allergy Clin. Immunol. 66:106–11 [Google Scholar]
  109. Sheffer AL, Soter NA, McFadden ER Jr, Austen KF. 109.  1983. Exercise-induced anaphylaxis: a distinct form of physical allergy. J. Allergy Clin. Immunol. 71:311–l6 [Google Scholar]
  110. Sheffer AL, Tong AKF, Murphy GF, Lewis RA, McFadden ER Jr, Austen KF. 110.  1985. Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. J. Allergy Clin. Immunol. 75:479–84 [Google Scholar]
  111. Soter NA, Wasserman SI, Austen KF, McFadden ER Jr. 111.  1980. Release of mast cell mediators and alterations in lung function in patients with cholinergic urticaria. N. Engl. J. Med. 302:604–8 [Google Scholar]
  112. Roberts LJ II, Lewis RA, Oates JA, Austen KF. 112.  1979. Prostaglandin, thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim. Biophys. Acta 575:185–92 [Google Scholar]
  113. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ II. 113.  1982. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129:1627–31 [Google Scholar]
  114. Roberts LJ II, Sweetman BJ, Lewis RA, Austen KF, Oates JA. 114.  1980. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N. Engl. J. Med. 303:1400–4 [Google Scholar]
  115. Soter NA, Austen KF, Wasserman SI. 115.  1979. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301:465–69 [Google Scholar]
  116. Donaldson VH, Evans RR. 116.  1963. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase. Am. J. Med. 35:37–44 [Google Scholar]
  117. Austen KF, Sheffer AL. 117.  1965. Detection of hereditary angioneurotic edema by demonstration of a profound reduction in the second component of human complement. N. Engl. J. Med. 272:649–56 [Google Scholar]
  118. Ruddy S, Austen KF. 118.  1967. A stoichiometric assay for the fourth component of complement in whole human serum using EAC'1agp and functionally pure human second component. J. Immunol. 99:1162–72 [Google Scholar]
  119. Spaulding WB. 119.  1955. Hereditary angioneurotic oedema in two families. Can. Med. Assoc. J. 73:181–87 [Google Scholar]
  120. Sheffer AL, Fearon DT, Austen KF. 120.  1979. Clinical and biochemical effects of impeded androgen (oxymethalone) therapy of hereditary angioedema (HAE). J. Allergy Clin. Immunol. 64:275–80 [Google Scholar]
  121. Sheffer AL, Fearon DT, Austen KF. 121.  1981. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J. Allergy Clin. Immunol. 68:181–87 [Google Scholar]
  122. Caldwell JR, Ruddy S, Schur PH, Austen KF. 122.  1972. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1:39 [Google Scholar]
  123. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS. 123.  1985. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N. Engl. J. Med. 312:534–40 [Google Scholar]
  124. Fearon DT. 124.  1980. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 152:20–30 [Google Scholar]
  125. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 125.  1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129:184–89 [Google Scholar]
  126. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. 126.  1983. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. USA 80:5066–70 [Google Scholar]
  127. Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP et al.127.  1972. Metabolism of third complement component (C3) in nephritis: role of the classical and alternate (properdin) pathways for complement activation. N. Engl. J. Med. 287:835–40 [Google Scholar]
  128. Daha MR, Fearon DT, Austen KF. 128.  1976. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J. Immunol. 116:1–7 [Google Scholar]
  129. Daha MR, Austen KF, Fearon DT. 129.  1977. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3b, Bb (C3NeF) and its release after decay of convertase function. J. Immunol. 19:812–17 [Google Scholar]
  130. Daha MR, Austen KF, Fearon DT. 130.  1978. Heterogeneity, polypeptide composition and antigenic reactivity of C3NeF. J. Immunol. 120:1389–94 [Google Scholar]
  131. Austen KF. 131.  2004. Acceptance of the Kober Medal: It only gets better. J. Clin. Invest. 114:1177 [Google Scholar]
/content/journals/10.1146/annurev.immunol.26.021607.090339
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error